MedTrace Logo

Brain Response to Serotonergic Medications in ASD

NCT04145076 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-04-15

No results posted yet for this study

Summary

This study investigates brain response to single acute dose of citalopram, tianeptine, and placebo in males with and without autism spectrum disorder.

Conditions

Interventions

DRUG

Placebo

Two oral doses of placebo.

DRUG

Citalopram

Single oral dose of citalopram (20mg) and single oral dose of placebo.

DRUG

Tianeptine

Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.

Sponsors & Collaborators

Principal Investigators

  • Grainne McAlonan, PhD · King's College London

  • Declan Murphy, PhD · King's College London

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-15
Primary Completion
2023-02-28
Completion
2023-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04145076 on ClinicalTrials.gov